Drugs / BCMA-GPRC5D CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07195617 | Oct 2025 → Nov 2027 | refractory plasma cell neoplasm | Guangzhou Bio-gene Technology Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-GPRC5DCAR-T | “This study is a single-arm, single-center clinical study, with the main purpose of IIT clinical trials to evaluate the safety and initial efficacy of BCMA-GPRC5DCAR-T cells in...” NCT07195617 ↗ |
| Known as | BCMA-GPRC5D CAR T cells | “BCMA-GPRC5D CAR T cells were transfused” NCT07195617 ↗ |
| Modality | Cell therapy | “BCMA-GPRC5DCAR-T cells” NCT07195617 ↗ |
| Route | Intravenous | “Eligible subjects received intravenous infusion of 2×106 /kg±50% CAR T cells.” NCT07195617 ↗ |